The widespread use of DPP-4 inhibitors among patients with T2DM and advanced age, who are more predisposed to osteoporosis, underscores the need for a better understanding of the relationship between DPP-4 enzyme activity, its substrates, pharmacological inhibition, and bone metabolism. The gene discussed is DPP4; the disease is osteoporosis.